ALTITUDE (2012) — Trial Summary
ALTITUDE (2012): The ALTITUDE trial evaluated whether direct renin inhibition with aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and CKD already on RAAS blockade.
References
- Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204-2213.